Petros Pharmaceuticals, Inc. – NASDAQ:PTPI
Petros Pharmaceuticals stock price today
Petros Pharmaceuticals stock price monthly change
Petros Pharmaceuticals stock price quarterly change
Petros Pharmaceuticals stock price yearly change
Petros Pharmaceuticals key metrics
Market Cap | 2.83M |
Enterprise value | N/A |
P/E | -0.09 |
EV/Sales | -0.14 |
EV/EBITDA | 0.06 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -4.91 |
Revenue | 4.69M |
EBITDA | -11.00M |
Income | -14.80M |
Revenue Q/Q | -44.84% |
Revenue Y/Y | -22.36% |
Profit margin | -285.66% |
Oper. margin | -283.11% |
Gross margin | 80.34% |
EBIT margin | -283.11% |
EBITDA margin | -234.47% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePetros Pharmaceuticals stock price history
Petros Pharmaceuticals stock forecast
Petros Pharmaceuticals financial statements
| Jun 2023 | 1.99M | -2.54M | -127.72% |
|---|---|---|---|
| Sep 2023 | 1.67M | -4.54M | -271.67% |
| Dec 2023 | -364.25K | 318.15K | -87.34% |
| Mar 2024 | 1.38M | -8.02M | -577.97% |
| 2025 | 5.47M | -7.09M | -129.57% |
|---|---|---|---|
| 2026 | 11.02M | -5.41M | -49.14% |
| 2027 | 20.62M | -1.63M | -7.91% |
| 2028 | 27.78M | 739.84K | 2.66% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 28727108 | 15.78M | 54.94% |
|---|---|---|---|
| Sep 2023 | 38914168 | 31.85M | 81.87% |
| Dec 2023 | 33795795 | 21.31M | 63.07% |
| Mar 2024 | 30312335 | 19.61M | 64.72% |
| Jun 2023 | -572.07K | 0 | -363.20K |
|---|---|---|---|
| Sep 2023 | -3.69M | 0 | 11.08M |
| Dec 2023 | -2.25M | 0 | -2.37M |
| Mar 2024 | -1.13M | 0 | -1.12M |
Petros Pharmaceuticals alternative data
| Aug 2023 | 24 |
|---|---|
| Sep 2023 | 24 |
| Oct 2023 | 24 |
| Nov 2023 | 24 |
| Dec 2023 | 24 |
| Jan 2024 | 24 |
| Feb 2024 | 24 |
| Mar 2024 | 24 |
| Apr 2024 | 24 |
| May 2024 | 21 |
| Jun 2024 | 21 |
| Jul 2024 | 21 |
Petros Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Oct 2021 | 3323614 | 0 |
| Nov 2021 | 875000 | 0 |
| Dec 2021 | 255102 | 0 |
| Insider | Compensation |
|---|---|
| Mr. Keith F. Lavan (1964) Advisor | $468,800 |
Mr. Fady Boctor M.B.A. (1977) Pres & Chief Commercial Officer | $467,850 |
Mr. Andrew Gesek M.B.A. (1970) Pres of Timm Medical Technologies | $407,420 |
Mr. Mitchell S. Arnold M.B.A. (1964) Vice President of Fin. & Chief Accounting Officer | $354,630 |
-
What's the price of Petros Pharmaceuticals stock today?
One share of Petros Pharmaceuticals stock can currently be purchased for approximately $0.03.
-
When is Petros Pharmaceuticals's next earnings date?
Unfortunately, Petros Pharmaceuticals's (PTPI) next earnings date is currently unknown.
-
Does Petros Pharmaceuticals pay dividends?
No, Petros Pharmaceuticals does not pay dividends.
-
How much money does Petros Pharmaceuticals make?
Petros Pharmaceuticals has a market capitalization of 2.83M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.83% to 5.82M US dollars.
-
What is Petros Pharmaceuticals's stock symbol?
Petros Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PTPI".
-
What is Petros Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Petros Pharmaceuticals?
Shares of Petros Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Petros Pharmaceuticals's key executives?
Petros Pharmaceuticals's management team includes the following people:
- Mr. Keith F. Lavan Advisor(age: 61, pay: $468,800)
- Mr. Fady Boctor M.B.A. Pres & Chief Commercial Officer(age: 48, pay: $467,850)
- Mr. Andrew Gesek M.B.A. Pres of Timm Medical Technologies(age: 55, pay: $407,420)
- Mr. Mitchell S. Arnold M.B.A. Vice President of Fin. & Chief Accounting Officer(age: 61, pay: $354,630)
-
How many employees does Petros Pharmaceuticals have?
As Jul 2024, Petros Pharmaceuticals employs 21 workers, which is 13% less then previous quarter.
-
When Petros Pharmaceuticals went public?
Petros Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 2 Dec 2020.
-
What is Petros Pharmaceuticals's official website?
The official website for Petros Pharmaceuticals is petrospharma.com.
-
Where are Petros Pharmaceuticals's headquarters?
Petros Pharmaceuticals is headquartered at 1185 Avenue of the Americas, New York, NY.
-
How can i contact Petros Pharmaceuticals?
Petros Pharmaceuticals's mailing address is 1185 Avenue of the Americas, New York, NY and company can be reached via phone at +973 2420005.
Petros Pharmaceuticals company profile:
Petros Pharmaceuticals, Inc.
petrospharma.comNASDAQ
21
Drug Manufacturers - Specialty & Generic
Healthcare
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
New York, NY 10036
CIK: 0001815903
ISIN: US71678J2096
CUSIP: 71678J100
